X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 25.3 44.8 56.4% View Chart
P/BV x 4.0 6.3 62.5% View Chart
Dividend Yield % 0.3 0.8 37.7%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
TORRENT PHARMA
Mar-18
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9931,550 64.1%   
Low Rs7291,144 63.8%   
Sales per share (Unadj.) Rs325.5354.7 91.8%  
Earnings per share (Unadj.) Rs39.340.1 98.1%  
Cash flow per share (Unadj.) Rs48.764.2 75.8%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.21.0 22.3%  
Book value per share (Unadj.) Rs159.2273.1 58.3%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.8 69.7%   
Avg P/E ratio x21.933.6 65.2%  
P/CF ratio (eoy) x17.721.0 84.4%  
Price / Book Value ratio x5.44.9 109.7%  
Dividend payout %5.134.9 14.6%   
Avg Mkt Cap Rs m242,991227,897 106.6%   
No. of employees `00013.014.7 88.2%   
Total wages/salary Rs m16,40811,353 144.5%   
Avg. sales/employee Rs Th7,083.94,083.0 173.5%   
Avg. wages/employee Rs Th1,265.4772.3 163.8%   
Avg. net profit/employee Rs Th855.1461.3 185.3%   
INCOME DATA
Net Sales Rs m91,85760,021 153.0%  
Other income Rs m3742,988 12.5%   
Total revenues Rs m92,23063,009 146.4%   
Gross profit Rs m20,36713,493 151.0%  
Depreciation Rs m2,6444,086 64.7%   
Interest Rs m2,3733,085 76.9%   
Profit before tax Rs m15,7249,310 168.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,529 151.3%   
Profit after tax Rs m11,0886,781 163.5%  
Gross profit margin %22.222.5 98.6%  
Effective tax rate %24.327.2 89.6%   
Net profit margin %12.111.3 106.8%  
BALANCE SHEET DATA
Current assets Rs m68,74652,623 130.6%   
Current liabilities Rs m27,02752,022 52.0%   
Net working cap to sales %45.41.0 4,532.0%  
Current ratio x2.51.0 251.5%  
Inventory Days Days85120 71.1%  
Debtors Days Days9676 125.3%  
Net fixed assets Rs m24,13285,016 28.4%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m44,64345,376 98.4%   
Net worth Rs m44,92546,222 97.2%   
Long term debt Rs m45,36341,115 110.3%   
Total assets Rs m117,639142,432 82.6%  
Interest coverage x7.64.0 189.8%   
Debt to equity ratio x1.00.9 113.5%  
Sales to assets ratio x0.80.4 185.3%   
Return on assets %11.46.9 165.2%  
Return on equity %24.714.7 168.2%  
Return on capital %19.114.2 134.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15214,580 385.1%   
Fx outflow Rs m8,0843,600 224.6%   
Net fx Rs m48,06810,980 437.8%   
CASH FLOW
From Operations Rs m6,5748,942 73.5%  
From Investments Rs m-7,124-47,070 15.1%  
From Financial Activity Rs m5,43234,174 15.9%  
Net Cashflow Rs m1,992-3,655 -54.5%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - IPCA LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS